Ceritinib for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer. Issue 2 (1st February 2016)

• Record Type: Journal Article
• Authors: Landi, Lorenza; Cappuzzo, Federico
• Is Part Of: Expert review of clinical pharmacology. Volume 9:Issue 2(2016)
• Page Start: 203
• Page End: 214
• Publication Date: 2016-02-01
• Subjects: Ceritinib -- ALK positive NSCLC -- crizotinib -- ALK-inhibitor -- acquired resistance -- oncogene-addicted NSCLC; Clinical pharmacology -- Periodicals; 615.105
• DOI: 10.1586/17512433.2016.1122518
• Languages: English
• ISSNs: 1751-2433

Abstract

ABSTRACT: Non-small cell lung cancer (NSCLC) represents the paradigm of personalized treatment of human cancer. Several oncogenic druggable alterations have been so far identified, with anaplastic lymphoma kinase ( ALK ) gene rearrangements representing one of the newest and most appealing. Crizotinib is now recognized as the standard of care in ALK -positive NSCLC due to the positive results of recently published trials. Unfortunately, resistance inevitably occurs within the first year of treatment. Overcoming resistance is the major challenge in clinical oncology, and novel potent ALK inhibitors are currently under evaluation, including ceritinib. Ceritinib is an oral, potent, second-generation ALK inhibitor demonstrating activity in patients who develop resistance to crizotinib. Recent data also suggested efficacy in ALK-inhibitor-naive population, thus supporting investigation of the drug in front-line setting.